CoChat

Pharmacokinetics and Pharmacodynamics of Fluvastatin in Heart Transplant Recipients Taking Cyclosporine A

Park, Jai-Wun, Siekmeier, Ruidiger, Lattke, Peter, Merz, Mechthild, Mix, Comnelia, Schuiler, Stefan, Jaross, Werner · 2001 · Journal of Cardiovascular Pharmacology and Therapeutics
Cited by 74

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Abstract

During the last decades, transplantation has become an established tool for the treatment of terminal organ failure. Beside immunological factors, hyperlipidemia is the main problem after heart transplantation, causing rapid transplant coronary artery disease (TxCAD) and poor long-term prognosis at the beginning of the transplantation. Heart transplant recipients are now effectively treated with lipid lowering substances, of which HMG-CoA-reductase inhibitors are the most potent. However, treatment with these substances correlates with an increased risk for the development of rhabdomyolysis due to therapy with the immunosuppressive cyclosporine A. Our study monitored the safety and efficacy of treatment with the HMG-CoA reductase inhibitor fluvastatin in heart transplant recipients compared to healthy controls. We investigated 10 patients receiving immunosuppressive therapy consisting of cyclosporine A, prednisone, and azathioprine who had increased concentrations of LDL-cholesterol (LDL-C), and 10 age-matched healthy controls. The patients were treated with 40 mg/day fluvastatin for 4 weeks and 20 mg/day for 4 additional weeks. Control individuals received 40 mg/day fluvastatin for 4 weeks only. Parameters of fluvastatin pharmacokinetics (maximum concentration of the drug (Cax,), time (tmax) to reach Cmax, area under the concentration vs. time curve (AUCOh 24h), elimination halflife time (t,2)), apparent total body clearance (CL), blood cyclosporine A concentration, plasma lipids, and safety parameters were determined in both study groups at the beginning of the study and after 4 weeks. The latter were determined in the patient group also after 8 and 12 weeks. Treatment with 40 mg/day fluvastatin caused a significant decrease in total cholesterol (patients: 5.47 ± 1.32 mmol/L vs. 7.30 ± 1.83 mmol/L; controls: 4.69 ± 0.64 mmolIL vs. 5.81 ± 0.72 mmol/L), LDL-C (patients: 3.28 + 1.25 mmol/L vs. 5.00 ± 1.85 mmol/L; controls: 2.58 ± 0.63 mmol/L vs. 3.50 ± 0.70 mmolJL), and triglycerides (patients: 1.99 ± 0.77 mmol/L vs. 2.50 ± 1.00 mmol/L; controls: 1.24 ± 0.46 mmolIL vs. 1.72 ± 0.67 mmol/L) in both study groups, whereas HDL-C was not significantly changed (patients: 1.29 ± 0.35 mmol/L vs. 1.17 ± 0.32 mmol/L; controls: 1.55 ± 0.30 mmol/L vs. 1.53 ± 0.26 mmol/L). Values of C,,m, and AUCOh 24h were higher in the patient group than in the control group (day 1, patients vs. controls, Cma,: 869.4 ± 604.0 ng/mL vs. 211.9 ± 113.9 ng/mL; AUCOh 24 h: 1948.8 ± 1347.9 ng/mL*h vs. 549.4 ± 247.4 ng/mLh), whereas the corresponding value of CL was lower in the patient group (33.3 ± 24.5 L/h vs. 107.9 ± 95.8 L/h), and the values of t,,,. and t,2 showed no differences. In addition, values of C,,m, and AUCOb 24h after administration of 40 mg/day fluvastatin for 4 weeks in both groups were slightly higher than at the beginning, whereas the value of CL was slightly lower (day 28, patients vs. controls, C,,a,: 1530.4 ± 960.4 ng/mL vs. 254.7 ± 199.8 ng/mL; AUCOb-240: 2615.3 ± 1379.4 ng/mL*h vs. 841.8 ± 421.4 ng/mL*h; CL: day 28, 21.4 ± 15.3 L/h vs. 61.5 ± 36.6 L/h). Except for an intermittent increase of creatine kinase, safety parameters showed no increases within the observation period. Our data suggest that fluvastatin effectively lowers plasma concentrations of cholesterol and LDL-C in patients after heart transplantation, however, the metabolism of fluvastatin is affected by concomitant therapy with cyclosporine A. Serum concentrations of fluvastatin should be monitored in cases of concomitant therapy with other substances interfering in the metabolism by competing cytochrome enzymes.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1177/107424840100600404

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Cited by

See all 74

Metadata

Authors
Park, J.-W., Siekmeier, R., Lattke, P., Merz, M., Mix, C., Schuiler, S., & Jaross, W.
Venue
Journal of Cardiovascular Pharmacology and Therapeutics
Published
2001-12
Volume
6
Issue
4
Pages
351-361
ISSN
  • 1074-2484 (ISSN-L)
  • 1940-4034
OpenAlex
W2170052837
Cited by
74
References
5
FWCI
4.35
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Pharmacokinetics and Pharmacodynamics of Fluvastatin in Heart Transplant Recipients Taking Cyclosporine A. https://app.cochat.ai/papers/10.1177/107424840100600404
The paper
Park, J.-W., Siekmeier, R., Lattke, P., Merz, M., Mix, C., Schuiler, S., & Jaross, W. (2001). Pharmacokinetics and Pharmacodynamics of Fluvastatin in Heart Transplant Recipients Taking Cyclosporine A. Journal of Cardiovascular Pharmacology and Therapeutics. https://doi.org/10.1177/107424840100600404

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.